“The third quarter was marked by strong operational execution across our portfolio,” said Pratik Shah, chairperson and chief executive officer of Design Therapeutics (DSGN). “Today we are excited to unveil DT-818 as our development candidate for the treatment of DM1, a debilitating neuromuscular disease with significant unmet medical need. With broad tissue distribution, significant splicing correction, and selectivity for mutant DMPK, we believe DT-818 has best-in-disease potential. Our DT-216P2 and DT-168 trials also continue to progress toward anticipated second half 2026 data readouts in FA and FECD. With these milestones, we are entering an exciting phase for Design as we advance multiple programs toward clinical proof-of-concept.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DSGN:
- Design Therapeutics Advances DT-168 Study for Fuchs Dystrophy
- Design Therapeutics Advances DT-216P2 Study for Friedreich’s Ataxia
- Design Therapeutics Advances with New Study on DT-216P2 for Friedreich Ataxia
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- Design Therapeutics Appoints Justin Gover as Director